文摘
摘要目的:调查的治疗效益鼻anti-CD3治疗我的动物模型。
背景:脑出血(我)是最具破坏性的类型的中风,不成比例的高死亡率接近40%。目前在我治疗的调查主要集中在限制血肿扩张,不幸的是,并没有导致一个有效的治疗方法。在post-ICH继发损伤神经炎症发挥重要作用。接触大脑血液制品薄壁组织发起一个复杂的炎症级联从居民小胶质细胞的激活。循环单核细胞和淋巴细胞产生的细胞因子释放新兵,进一步增强炎症,造成二次伤害。的细胞和分子机制导致神经赤字之后我知之甚少,而且没有有效的疗法来调节缓解中枢神经系统损伤,促进经济复苏。粘膜免疫系统是一个独特的耐受性的器官,它提供了一个生理途径诱导调节性T细胞亚群)。我们发现鼻anti-CD3单克隆抗体诱发IL-10-secreting treg迁移到大脑和抑制小胶质炎症的小鼠模型多发性硬化症。亚/ il - 10的治疗潜力轴我很大程度上是未知的。
设计/方法:我们采用胶原酶模型小鼠和管理我的鼻anti-CD3治疗在24小时内我月post-bleed继续了。我们进行了流式细胞术、组织病理学和行为分析的细胞和评估治疗的效果在月post-ICH行为结果。
结果:鼻anti-CD3 FoxP3 + treg和IL10生产FoxP3 + treg增加大脑中。它还减少小胶质激活和病变侧半球post-ICH体积。治疗改善行为的结果,包括电动机、空间学习、和月post-ICH hippocampal-dependent工作记忆功能。
结论:我们的研究表明,鼻anti-CD3可能代表一个新颖的治疗方法治疗我和潜在的其他类型的急性脑损伤。
披露:依奇博士已经收到相关出版物的出版版税卫生保健。Taha Yahya没有披露。曹博士没有披露。佤邦博士没有披露。Moreira博士没有披露。Rezende博士没有披露。Weiner博士已经收到个人薪酬在500 - 4999美元的范围为基因泰克公司担任顾问。Weiner博士已经收到个人薪酬在500 - 4999美元的范围作为顾问Medday制药。Weiner博士已经收到个人薪酬在10000 - 49999美元的范围作为顾问vTv疗法。Weiner博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会iziana生命科学。 Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has received stock or an ownership interest from vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
